Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PTGFR | P43088 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9623610 | 0.91 | LMNA (0.66) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL926838 | 0.87 | LMNA (0.60) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL1470380 | 0.85 | LMNA (0.63) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL15067061 | 0.85 | LMNA (0.58) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL6305137 | 0.85 | MAPK1 (0.45) | LMNAMAPK1HTTRAB9APRKAB2 | |
| SCHEMBL9622934 | 0.84 | PKM (0.60) | LMNAMAPK1HTTRAB9APOLB | |
| SCHEMBL9440011 | 0.84 | THRA (0.66) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL1749795 | 0.84 | THRA (0.62) | LMNAMAPK1HTTRAB9ATHRA | |
| Hydrochloric Acid SCHEMBL30460803 | 0.84 | MAPK1 (0.44) | LMNAMAPK1HTTRAB9APRKAB2 | |
| SCHEMBL9623405 | 0.84 | LMNA (0.57) | LMNAMAPK1HTTRAB9ATHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | LMNA 3819/4885MAPK1 1867/4885HTT 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.